Liptruzet

Atorvastatin calcium and ezetimibe, the active ingredients in Liptruzet, are a statin/cholesterol absorption inhibitor combination presented as a tablet for oral use. They lower elevated cholesterol and other lipids in adults with primary hyperlipidemia, mixed dyslipidemia, or familial hypercholesterolemia.

GNH USA supplies Liptruzet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory‑approved batches to global healthcare providers.

Liptruzet is indicated for several lipid disorders and works by reducing cholesterol synthesis and absorption.

- Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Primary hyperlipidemia: lowers elevated triglycerides and improves overall lipid profile. - Mixed dyslipidemia: decreases both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol. - Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when diet and statin monotherapy are insufficient.

Liptruzet may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Diarrhea: loose stools, usually transient. - Abdominal pain: discomfort in the stomach area. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: significant elevation of liver enzymes or jaundice. - Severe allergic reaction: rash, angioedema, or anaphylaxis. - Acute pancreatitis: sudden abdominal pain with elevated pancreatic enzymes.

Before prescribing Liptruzet, clinicians should consider several precautionary measures to ensure patient safety.

- Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal impairment assessment: adjust therapy in patients with severe kidney disease. - Drug‑induced myopathy vigilance: monitor for unexplained muscle pain or weakness. - Pregnancy and lactation counseling: avoid use unless benefits outweigh risks. - Concomitant medication review: evaluate for potential interactions with CYP3A4 inhibitors or fibrates. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Liptruzet can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase atorvastatin exposure and risk of myopathy. - Cyclosporine: raises both atorvastatin and ezetimibe levels, heightening toxicity. - Gemfibrozil: combined use significantly raises risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Warfarin: statins can potentiate anticoagulant effect, requiring INR monitoring. - Niacin: may increase risk of liver enzyme elevations.